NEW YORK (360Dx) – Abbott said today that it has inked a $252 million managed equipment services contract with North West London Pathology for the supply of analytical equipment and consumables.
Under the terms of the deal, the firm will supply its Alinity ci clinical chemistry and immunoassay and Alinity h hematology diagnostics instruments, as well as its AlinIQ professional services and informatics solution. The partnership is expected to manage 26 million tests per year, and will hold 6 percent of the total pathology market in the UK, Abbott said.
Mike Clayton, managing director of Abbott's diagnostics business in Northern Europe, said in a statement that the deal will "equip NWLP to help maximize productivity, drive faster delivery of test results, and provide the critical information needed for clinical decisions — with the goal of helping the Trust improve patient outcomes."
Imperial College Healthcare NHS Trust in London, Westminster NHS Foundation Trust, and the Hillingdon Hospitals NHS Foundation Trust consolidated their pathology services into NWLP earlier this year to better manage demand, standardize operations, improve value for money, and make use of new technologies, Abbott said.
The hospitals included within the partnership are Imperial College Healthcare NHS Trust, which consists of St. Mary's Hospital, Charing Cross Hospital, Hammersmith Hospital, Queen Charlotte and Chelsea Hospital, and the Western Eye Hospital; Chelsea & Westminster Hospital Foundation Trust, which consists of Chelsea & Westminster Hospital and West Middlesex University Hospital; and Hillingdon Hospitals NHS Foundation Trust, which consists of Hillingdon Hospital and Mount Vernon Hospital.
NWLP, hosted by Imperial College Healthcare NHS Trust, conducted a competitive procurement process in advance of awarding the contract, Abbott said.